Another big biopharma merger runs into another snag at the FTC. What now?
It’s AbbVie’s turn to get hit with a dreaded second request for information from the FTC regarding its $63 billion megamerger with Allergan.
Right on the heels of the latest delay for the Roche/Spark tie-up, the FTC has some unfinished business with AbbVie, which has its eyes on Allergan’s lucrative Botox franchise.
There is, of course, no word on what the latest FTC inquiry is all about, but the experts say every second request comes with an odds-on demand — running at 80% — for a divestiture to satisfy antitrust concerns.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 70,000+ biopharma pros reading Endpoints daily — and it's free.